LCM
TRIL

Laurion Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Laurion Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-489,084
Closed -$4.74M – 930
2021
Q2 		$4.74M Sell
489,084
-510,916
-51% -$4.81M 0.03% 283
2021
Q1 		$10.7M Hold
1,000,000
– – 0.06% 246
2020
Q4 		$14.7M Buy
1,000,000
+573,833
+135% +$8.27M 0.11% 156
2020
Q3 		$6.06M Buy
+426,167
New +$4.25M 0.07% 207

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Laurion Capital Management's TRIL Position: Q3 2021 in Review

Laurion Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 489,084 shares — an estimated $4.74M sold.

Laurion Capital Management first reported a position in TRIL in Q3 2020 and held it in 4 quarters. The position peaked at $14.7M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Laurion Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Laurion Capital Management sold 489,084 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $4.74M.
  • Laurion Capital Management first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 4 quarters.
  • Laurion Capital Management's Trillium Therapeutics Inc. position peaked at $14.7M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.